Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals

Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;

More than 1000 medicines of different brands show marked Price reduction;

Estimated annual savings to consumers expected to be above ₹3500 crore

Posted On: 07 NOV 2026 3:51PM by PIB Delhi

National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026. The revised prices of these drugs will come into effect from 9th November, 2026.

As on date, 76 pharmaceutical companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. Further, out of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalization (TMR) will be applicable on these drugs also as and when they are launched.

As a result of the price reductions to be effected from 9th November, 2026, the estimated annual savings to consumers would be ₹3,502.31 crore.

List of major anti-cancer brands with revised prices

Formulation	Brand Name	Company Name	Old MRP (₹)	Revised MRP (₹)

Bevacizumab 100 MG Injection: Used for Lung, Colon, Ovary and Cervical Cancer	Bryxta	Zydus Lifesciences Limited	25,995.00	3,318.0
	BevaciRel	Reliance Life Sciences Private Limited	24,079.00	3,985.0
	CIZUMAB	HETERO HEALTHCARE LTD	15,658.00	3,103.0
	Versavo	Dr. Reddys Laboratories Limited	7,686.00	3,504.2
Denosumab 60 MG Injection: Used for breast and prostate cancer (prevents bone loss)	DenOsteoRel	Reliance Life Sciences Private Limited	24,955.00	6,240.0
	Debrumab	RPG LIFE SCIENCES LTD	22,031.25	5,941.0
	Denoclast	Zydus Lifesciences Limited	19,687.50	7,334.8
	ROZEL	INTAS PHARMACEUTICALS LTD	15,458.40	6,825.5
Abiraterone acetate 250 MG Tablet: Used for Prostate Cancer	ABIRONE	ARVINCARE PHARMA PVT LTD	41,250.00	3,218.2
	ABIRAT	Khandelwal Laboratories Private Limited	36,088.81	4,064.4
	AHABIR	HETERO HEALTHCARE LTD	33,876.50	4,925.0
	Abirapro	Glenmark Pharmaceuticals Ltd.	28,744.00	5,768.0

Pegfilgrastim 6 MG Injection: To prevent neutropenia in cancer patients	PEG FILTERO	HETERO HEALTHCARE LTD	9,093.00	1,631.0
	Peg-ReliGrast	Reliance Life Sciences Private Limited	5,331.00	1,258.0
	Pegex	Gennova Biopharmaceuticals Ltd.	6,270.45	1,527.7
	Peg Frastim	RPG LIFE SCIENCES LTD	6,660.85	1,807.0
Azacitidine 100 MG Injection: Used for Blood Cancer	AzatiRel	Reliance Life Sciences Private Limited	7,790.00	1,397.0
	AZADINE	INTAS PHARMACEUTICALS LTD	5,964.70	1,199.5
	Azacytin	Dr. Reddys Laboratories Limited	6,337.00	1,495.0
	Azadual 100	MSN LABORATORIES PRIVATE LIMITED	4,852.03	1,207.8
Enzalutamide 40 MG Capsule: Used for prostate cancer	ENZAPTOR 40	HALSTED PHARMA PVT LTD	20,625.00	2,475.6
	XTIDE	ERIS LIFESCIENCES LIMITED	10,828.12	1,729.2
	Enzuta	Emcure Pharmaceuticals Ltd.	20,667.00	4,157.6
	ENZAMIDE	INTAS PHARMACEUTICALS LTD	10,781.25	3,536.5

Fulvestrant 250 mg Injection: Used for breast cancer	FASNORM	ERIS LIFESCIENCES LIMITED	30,421.87	3,671.7
	FULZOS	HETERO HEALTHCARE LTD	16,500.00	3,215.0
	Fulvira	Emcure Pharmaceuticals Ltd.	16,694.95	3,900.4
	FISTENT INJ	Adley Formulations Pvt.Ltd	22,600.00	6,031.5
Palbociclib 125 MG Capsule: Used for breast cancer	Palbopro	RPG LIFE SCIENCES LTD	40,421.33	2,720.0
	PALBOMED	Medicamen Biotech Limited	13,500.00	2,302.0
	PICLIB	HETERO HEALTHCARE LTD	7,801.50	2,058.0
	Palborest 125	MSN LABORATORIES PRIVATE LIMITED	2,246.00	791.80
Pemetrexed 500 MG Vial: Used for lung cancer	ReliTrexed	Reliance Life Sciences Private Limited	9,977.00	1,113.0
	PEMETOMED	Medicamen Biotech Limited	5,062.00	940.00
	ADPEM 500	Adley Formulations Pvt.Ltd	5,499.00	1,035.0
	Pemgem	Dr. Reddys Laboratories Limited	7,032.00	3,408.6
Pertuzumab 420 MG Injection: Used for breast cancer	LUPIHER 2	Lupin Limited	83,520.00	37,358.
	Womab	Dr. Reddys Laboratories Limited	74,992.50	53,708.

TMR of non-scheduled anti-cancer medicines is an important step taken by the Government in its continued efforts to improve affordability and accessibility of essential anti-cancer medicines for cancer care.

The notification SO 5690 (E) dated 17th October, 2026 will remain in force until further orders However, manufacturers can avail annual price increase in accordance with the provisions of Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to continued compliance with the maximum permissible trade margin of 30%

Every retailer, dealer, hospital and institution is required to prominently display Revised MRP list of anti-cancer medicines on their websites and in their premises. As per the NPPA notification, State Drug Controllers will monitor compliance by manufacturers, dealers, Hospitals and Medical Institutions. Consumers can check the applicable prices through the **Pharma Sahi Daam mobile application** and the **NPPA website** (www.nppa.gov.in) and report any non-compliance or violation of revised prices to the authority.

Complaints can be submitted through the following channels:

Email: monitoring-nppa[at]gov[dot]in

Helpline: 1800-11-1255

Post: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001.

*****

PC/PM

(Release ID: 2333949) Visitor Counter : 777
Read this release in: Urdu , Marathi , हिन्दी , Bengali , Gujarati , Odia , Tamil , Kannada , Malayalam

Share

723 words | 3 min read